The latest price target for HCA Healthcare (NYSE:HCA) was reported by TD Cowen on March 10, 2026. The analyst firm set a price target for $561.00 expecting HCA to rise to within 12 months (a possible 14.77% upside). 55 analyst firms have reported ratings in the last year.

The latest analyst rating for HCA Healthcare (NYSE:HCA) was provided by TD Cowen, and HCA Healthcare maintained their buy rating.

The last upgrade for HCA Healthcare Inc happened on May 29, 2025 when Wells Fargo raised their price target to $385. Wells Fargo previously had an underweight for HCA Healthcare Inc.

The last downgrade for HCA Healthcare Inc happened on December 15, 2025 when Morgan Stanley changed their price target from $425 to $425 for HCA Healthcare Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HCA Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HCA Healthcare was filed on March 10, 2026 so you should expect the next rating to be made available sometime around March 10, 2027.

While ratings are subjective and will change, the latest HCA Healthcare (HCA) rating was a maintained with a price target of $529.00 to $561.00. The current price HCA Healthcare (HCA) is trading at is $488.78, which is out of the analyst’s predicted range.